Peripheral T-Cell Lymphoma
Status:
Published in Medical Letter on the CDC and FDA, January 13th, 2008
Allos Therapeutics, Inc. (NASDAQ:ALTH) announced that an independent Data Monitoring Committee (DMC) has completed the pre-specified 65-patient safety review of data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and has recommended that the trial continue per the protocol. This interim assessment was based upon an evaluation of patients enrolled in the study who completed at least one cycle of treatment with PDX. The Company currently expects to complete patient enrollment in the PROPEL study in the second quarter of 2008.
"The DMC recommendation represents another...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Drug Resistance
Pfizer Receives Approvable Letter from FDA for Dalbavancin - Cancer Gene Therapy
Data on cancer gene therapy discussed by K. Grønbaek and colleagues - Nanospheres
Researchers from Gwangju Institute of Science and Technology detail new studies and findings in the area of nanospheres - Anthrax
Studies from H.F. Duan and co-researchers update current data on anthrax - Chemical Warfare
Data from University of Oxford provide new insights into chemical warfare - Human Papillomavirus Vaccines
New data from Creighton University illuminate research in human papillomavirus vaccines - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
